InflaRx NV
IFRX1.110USD
+0.050+4.72%
收盘 12/19, 16:00（美东）报价延迟15分钟
75.20M总市值
亏损市盈率 TTM
关于 InflaRx NV 公司
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV简介
公司代码IFRX
公司名称InflaRx NV
上市日期Nov 08, 2017
CEORiedemann (Niels C)
员工数量74
证券类型Ordinary Share
年结日Nov 08
公司地址Winzerlaer Str. 2
城市JENA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Germany
邮编07745
电话493641508180
网址https://www.inflarx.de/
公司代码IFRX
上市日期Nov 08, 2017
CEORiedemann (Niels C)
InflaRx NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
收入明细
单位: USD更新时间: 3月5日 周三
单位: USD更新时间: 3月5日 周三
FY2022
FY2021
FY2020
FY2019
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Germany
0.00
0.00%
United States
0.00
0.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
其他
77.94%
持股股东
持股股东
占比
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
其他
77.94%
股东类型
持股股东
占比
Hedge Fund
17.39%
Individual Investor
6.38%
Research Firm
5.02%
Venture Capital
2.91%
Investment Advisor
1.12%
Investment Advisor/Hedge Fund
1.06%
Bank and Trust
0.02%
其他
66.11%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
77
16.63M
24.55%
-5.58M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Jun 30, 2025
683 Capital Management LLC
2.48M
3.65%
-150.00K
-5.71%
Jun 30, 2025
RA Capital Management, LP
1.97M
2.91%
+1.97M
--
Jun 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.64M
2.42%
-35.55K
-2.12%
Jun 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Ikarian Capital LLC
705.01K
1.04%
+705.01K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
693.35K
1.02%
-567.80K
-45.02%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
InflaRx NV的前五大股东是谁？
InflaRx NV 的前五大股东如下：
Suvretta Capital Management, LLC持有股份：6.48M，占总股份比例：9.57%。
683 Capital Management LLC持有股份：2.48M，占总股份比例：3.65%。
RA Capital Management, LP持有股份：1.97M，占总股份比例：2.91%。
Guo (Renfeng M.D.)持有股份：1.76M，占总股份比例：2.60%。
Eversept Partners, LP持有股份：1.64M，占总股份比例：2.42%。
Suvretta Capital Management, LLC持有股份：6.48M，占总股份比例：9.57%。
683 Capital Management LLC持有股份：2.48M，占总股份比例：3.65%。
RA Capital Management, LP持有股份：1.97M，占总股份比例：2.91%。
Guo (Renfeng M.D.)持有股份：1.76M，占总股份比例：2.60%。
Eversept Partners, LP持有股份：1.64M，占总股份比例：2.42%。
InflaRx NV的前三大股东类型是什么？
InflaRx NV 的前三大股东类型分别是：
Suvretta Capital Management, LLC
BofA Global Research (US)
683 Capital Management LLC
Suvretta Capital Management, LLC
BofA Global Research (US)
683 Capital Management LLC
有多少机构持有InflaRx NV(IFRX)的股份？
截至2025Q3，共有77家机构持有InflaRx NV的股份，合计持有的股份价值约为16.63M，占公司总股份的24.55%。与2025Q2相比，机构持股有所增加，增幅为-12.91%。
哪个业务部门对InflaRx NV的收入贡献最大？
在FY2022，--业务部门对InflaRx NV的收入贡献最大，创收--，占总收入的--%。
